Systematic Review and Network Meta ‐Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen Deprivation Therapy to Reduce Risk of Fragility Fractures

ConclusionDenosumab and zoledronic acid may have stronger evidence, but all treatments are effective in reducing the rate of bone loss in our patient population. The key policy implication is that men who are at risk for fracture should receive some form of osteoporosis treatment. Choosing the optimal drug should be based on efficacy, safety, product availability, patient preferences and costs.This article is protected by copyright. All rights reserved.

Source: BJU International - September 18, 2017 Category: Urology & Nephrology Authors: Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary ‐Ellen Hogan, Murray Krahn Tags: Review Source Type: research